Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin
Gabriele Buda, Deborah Ricci, C. Chris Huang, Reyna Favis, Nadine Cohen, Sen H. Zhuang, Jean-Luc Harousseau, Pieter Sonneveld, Joan Bladé, Robert Z. OrlowskiVolume:
89
Langue:
english
Pages:
8
DOI:
10.1007/s00277-010-0992-3
Date:
November, 2010
Fichier:
PDF, 264 KB
english, 2010